1. Home
  2. ELMD vs SGMT Comparison

ELMD vs SGMT Comparison

Compare ELMD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electromed Inc.

ELMD

Electromed Inc.

HOLD

Current Price

$38.41

Market Cap

208.1M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.07

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELMD
SGMT
Founded
1992
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.1M
169.4M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
ELMD
SGMT
Price
$38.41
$7.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$36.00
$26.13
AVG Volume (30 Days)
127.8K
1.3M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
46.55
N/A
EPS
0.91
N/A
Revenue
$54,716,000.00
$2,000,000.00
Revenue This Year
$15.59
N/A
Revenue Next Year
$11.51
N/A
P/E Ratio
$41.96
N/A
Revenue Growth
13.83
N/A
52 Week Low
$17.73
$4.50
52 Week High
$47.40
$10.46

Technical Indicators

Market Signals
Indicator
ELMD
SGMT
Relative Strength Index (RSI) 40.66 47.42
Support Level $35.61 $7.04
Resistance Level $40.00 $7.39
Average True Range (ATR) 2.17 0.44
MACD -1.01 -0.08
Stochastic Oscillator 9.48 21.77

Price Performance

Historical Comparison
ELMD
SGMT

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: